The present invention relates to peptides derived from COVID-19 virus envelope protein and spike protein. The invention further relates to polynucleotides and vectors encoding said peptides, and antibodies and chimeric antigen receptors that bind to said peptides. The invention also relates to methods of diagnosis and prediction of conditions in a subject which leverage recognition of said peptides, such as by antigen-specific T cells.

The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.

Provided herein are, inter alia, a T-cell comprising a nucleic acid including a sequence encoding an anti-HIV Chimeric Antigen Receptor (CAR) and a sequence encoding a protein inhibitor. Methods for making the T-cells and for using the T-cells to treat HIV-infected patients are provided.

Provided herein are, inter alia, a T-cell comprising a nucleic acid including a sequence encoding an anti-HIV Chimeric Antigen Receptor (CAR) and a sequence encoding a protein inhibitor. Methods for making the T-cells and for using the T-cells to treat HIV-infected patients are provided.

The present technology relates generally to compositions and methods for creating recombinant T cell receptor (TCR) libraries and methods of their therapeutic use. The compositions and methods of the present technology are useful for rapid isolation of antigen-specific TCR repertoires as personalized, targeted therapies for cancer and viral infection.

The present technology relates generally to compositions and methods for creating recombinant T cell receptor (TCR) libraries and methods of their therapeutic use. The compositions and methods of the present technology are useful for rapid isolation of antigen-specific TCR repertoires as personalized, targeted therapies for cancer and viral infection.

Provided herein are compositions with an augmented capacity to mediate ADCC. These compositions include chimeric NK cellscalled Nukes (NK Enhancement Strategy) that express CD64 Fc receptor from an exogenous nucleic acid molecule, the NK cells having antibodies bound thereto. Methods of using these cells for treatment of HIV, cancer, SARS-COV-2, and other diseases are provided.

Provided herein are compositions with an augmented capacity to mediate ADCC. These compositions include chimeric NK cellscalled Nukes (NK Enhancement Strategy) that express CD64 Fc receptor from an exogenous nucleic acid molecule, the NK cells having antibodies bound thereto. Methods of using these cells for treatment of HIV, cancer, SARS-COV-2, and other diseases are provided.

The present invention provides a T cell receptor (TCR) targeting a cytomegalovirus (CMV) antigen, a T cell expressing the TCR, and an application. Specitically, disclosed in the present invention are a specific T cell for HLA-A*0201-restricted targeting of a CMV-pp65 antigenic epitope and an application thereof. The TCR carried by the T cell can specifically target CMV-pp65, and clear the CMV precisely and quickly.

The present invention provides a T cell receptor (TCR) targeting a cytomegalovirus (CMV) antigen, a T cell expressing the TCR, and an application. Specitically, disclosed in the present invention are a specific T cell for HLA-A*0201-restricted targeting of a CMV-pp65 antigenic epitope and an application thereof. The TCR carried by the T cell can specifically target CMV-pp65, and clear the CMV precisely and quickly.